European CHMP recommends license extension of osimertinib (Tagrisso) for treatment of non-small cell lung cancer

The proposed license extension is for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

Source:

European Medicines Agency